Results 71 to 80 of about 69,107 (331)

Substrate specificity and structural investigation into PepO and PepW : two peptidases from Lactobacillus rhamnosus : a thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Biochemistry at Massey University, Palmerston North, New Zealand [PDF]

, 2005
The proteolytic systems of lactic acid bacteria have important roles in the maturation and flavour development of cheese. Lactic acid bacteria pepetidases contribute to the taste of cheese through the production of low-molecular weight peptides and free ...
Yates, Karen Maree
core  

The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]

, 2013
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core   +2 more sources

Effectiveness of Pre‐Transplant Dual GLP‐1 Receptor Agonist and SGLT2 Inhibitor Therapy on All‐Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target‐Trial Emulation

Advanced Science, EarlyView.
This target trial emulation in solid organ transplant candidates with obesity and type 2 diabetes evaluates whether pre‐transplant dual therapy with GLP‐1 receptor agonists plus SGLT2 inhibitors is associated with post‐transplant mortality and kidney graft outcomes compared with monotherapy or usual care, using multinational electronic health records ...
Yu‐Nan Huang, Min‐Yu Tsou, Pin‐Hung Li, Jo‐Ching Chen, Yen‐Liang Liu, Gideon Meyerowitz‐Katz, Tsung‐Hsun Tsai, Pen‐Hua Su   +7 more
wiley   +1 more source

Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease

Cardiovascular Diabetology, 2012
Background Diabetic patients present with an accelerated atherosclerotic process and an increased risk for future cardiovascular events. In addition to the risk imposed by the disease itself, pharmacological treatment adds also a sizable risk, especially
Klempfner Robert, Leor Jonathan, Tenenbaum Alexander, Fisman Enrique Z, Goldenberg Ilan   +4 more
doaj   +1 more source

Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis

Diabetology & Metabolic Syndrome, 2021
Background Dipeptidyl peptidase 4 (DPP4) is a serine exopeptidase able to inactivate various oligopeptides, and also a hepatokine. Hepatocyte-specific overexpression of DPP4 is associated with hepatic insulin resistance and liver steatosis.
Sachiko Hattori, Kazuomi Nomoto, Tomohiko Suzuki, Seishu Hayashi   +3 more
doaj   +1 more source

DPP-4 inhibitor dose selection according to manufacturer specifications:A Contemporary Experience From UK General Practice [PDF]

, 2019
Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests.
Busse, Michael, Gollop, Nicholas D., Marcus, Michael W., Spanopoulos, Dionysis, Tebboth, Abigail, Webb, Joanne   +5 more
core   +1 more source

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

Advanced Science, EarlyView.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo, Lanjie Lei, Ying Jin, Lan Su, Shumao Cui, Liyun Shi   +5 more
wiley   +1 more source

miR-29b Mediates the Chronic Inflammatory Response in Radiotherapy-Induced Vascular Disease

JACC: Basic to Translational Science, 2019
Summary: As a consequence of the success of present-day cancer treatment, radiotherapy-induced vascular disease is emerging. This disease is caused by chronic inflammatory activation and is likely orchestrated in part by microRNAs.
Suzanne M. Eken, MD, PhD, Tinna Christersdottir, MD, Greg Winski, MD, Traimate Sangsuwan, MSc, Hong Jin, MD, PhD, Ekaterina Chernogubova, PhD, John Pirault, PhD, Changyan Sun, MSc, Nancy Simon, MSc, Hanna Winter, MSc, Alexandra Backlund, PhD, Siamak Haghdoost, PhD, Göran K. Hansson, MD, PhD, Martin Halle, MD, PhD, Lars Maegdefessel, MD, PhD   +14 more
doaj   +1 more source

Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials

Journal of Diabetes Investigation, 2020
Aims/Introduction To explore the factors associated with the glucose‐lowering efficacy of sitagliptin treatment in Japanese patients with type 2 diabetes mellitus.
Naoko Tajima, Jun‐ichi Eiki, Taro Okamoto, Kotoba Okuyama, Masaru Kawashima, Samuel S Engel   +5 more
doaj   +1 more source

Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration

OncoImmunology, 2023
Radiotherapy could regulate systemic antitumor immunity, while the immune state in the tumor microenvironment (TME) also affects the efficacy of radiotherapy.
Yu Tian, Lingyi Kong, Yan Li, Zhiyun Liao, Xing Cai, Suke Deng, Xiao Yang, Bin Zhang, Yijun Wang, Zhanjie Zhang, Bian Wu, Lu Wen, Fang Huang, Yan Hu, Chao Wan, Yifei Liao, Yajie Sun, Kunyu Yang   +17 more
doaj   +1 more source